GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Femasys Inc (NAS:FEMY) » Definitions » Cash per Share

FEMY (Femasys) Cash per Share : $0.15 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Femasys Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Femasys's Cash per Share for the quarter that ended in Dec. 2024 was $0.15.

Femasys Cash per Share Historical Data

The historical data trend for Femasys's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Femasys Cash per Share Chart

Femasys Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash per Share
Get a 7-Day Free Trial 0.28 2.10 1.09 1.00 0.15

Femasys Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 0.81 0.61 0.34 0.15

Femasys Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Femasys's Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=3.452/23.36
=0.15

Femasys's Cash per Share for the quarter that ended in Dec. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=3.452/23.36
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Femasys  (NAS:FEMY) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Femasys Cash per Share Related Terms

Thank you for viewing the detailed overview of Femasys's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Femasys Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Femasys Inc (NAS:FEMY) » Definitions » Cash per Share
Comparable Companies
POCI HBIO IMTH RVP NXGL DXR NEPH EKSO MHUA POAI ISRG XPAR:EL BDX XSWX:ALC TSE:7741 RMD TSE:4543 OCSE:COLO B XSWX:STMN XPAR:DIM
Traded in Other Exchanges
N/A
Address
3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024
Website
https://www.femasys.com
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Executives
Keith J Kendall director 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alistair Milnes director C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Christine E Thomas officer: SVP, Regulatory & Clinical 2836 SW 117TH STREET, GAINESVILLE FL 32606
Dov Elefant officer: Chief Financial Officer EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Wendy Perrow director C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Edward Evantash officer: Chief Medical Officer 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
John Dyett director, 10 percent owner 11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025
Adams John Q Jr director 35 WYCK HILL LANE, WESTLAKE TX 76262
Edward R Uzialko director, 10 percent owner 4605 DUDLEY LANE, ATLANTA GA 30327
Charles Larsen director 28 SANDPIPER ROAD, TAMPA FL 33609
Kathy Lee-sepsick director, officer: Chief Executive Officer 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Daniel Scott Currie officer: Senior VP, Operations 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Kelley Hoskin Violet Alexandria officer: VP, Clinical & Medical Affairs 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Gary Thompson director 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
William Benson Witte director 11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025